A recent study in vivo showed that EGFR E746-A750 deletion mutant lung cancer can induce DC anergy and inhibit antitumor immunity, while T-cell infiltration and DC function were restored; meanwhile, the efficacy of ICIs in EGFR-19del tumors was improved because of the use of TKIs in combination with granulocyte-macrophage colony-stimulating factor (78). This evidence concerns the gene EGFR and lung cancer.